Related Experiment Video

Updated: Aug 11, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Choosing the right combination therapy in severe community-acquired pneumonia

Grant W Waterer1, Jordi Rello

  • 1School of Medicine and Pharmacology, University of Western Australia, MRF Building, Royal Perth Hospital, GPO Box X2213, Perth 6847, Australia. waterer@cyllene.uwa.edu.au

Critical Care (London, England)
|February 14, 2006
PubMed

Insights

For severe community-acquired pneumonia (CAP), combining a cephalosporin with a macrolide may be more effective than using a cephalosporin with a fluoroquinolone. This finding has implications for CAP treatment strategies.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Critical Care Medicine

Background:

  • Severe community-acquired pneumonia (CAP) often requires combination antibiotic therapy.
  • Monotherapy may be less effective than combination therapy for severe CAP.
  • The choice of antibiotics in combination regimens is critical.

Purpose of the Study:

  • To compare the effectiveness of two different combination antibiotic therapies for severe CAP.
  • To evaluate whether cephalosporin-fluoroquinolone therapy is inferior to cephalosporin-macrolide therapy.
  • To identify optimal antibiotic strategies for severe CAP.

Main Methods:

  • Retrospective data analysis of patients with severe CAP.
  • Comparison of treatment outcomes between patients receiving cephalosporin-fluoroquinolone and cephalosporin-macrolide regimens.
  • Statistical analysis to determine treatment efficacy and safety.

Main Results:

  • Combination therapy with a cephalosporin and a fluoroquinolone was found to be inferior to therapy with a cephalosporin and a macrolide.
  • Evidence suggests potential differences in efficacy between fluoroquinolone and macrolide components in combination therapy.
  • Further research is needed to confirm these findings.

Conclusions:

  • The combination of a cephalosporin and a macrolide may be a preferred treatment for severe CAP over a cephalosporin and a fluoroquinolone.
  • Physicians should consider these findings when selecting antibiotic regimens for severe CAP.
  • Mechanisms underlying the potential inferiority of fluoroquinolones in this context warrant further investigation.

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation